secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0000950170-24-107988
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet ADI-001 shows robust tissue trafficking, complete B cell depletion in Phase 1
--------------------------------------------------------------------------------

- Mean exposure of 236,701 CAR T cells per million in lymph node biopsies across all dose levels.
- At 1E9 dose, 27-64% of total cellular material in evaluable biopsies, exceeding published autologous alpha-beta CAR T levels.
- Complete CD19+ B cell depletion observed in secondary lymphoid tissue concurrent with trafficking and activation.
- Data highlight potential best-in-class profile vs. anti-CD20 antibodies that failed to deplete B cells in tissues.
- Initial clinical data from autoimmune programs (lupus nephritis, SLE, systemic sclerosis, AAV) expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024107988/0000950170-24-107988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024107988/acet-20240919.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer